| 摘要 |
The invention comprises the compound 9-(11-methylpiperidino - 31 - methyl) thioxanthene and its acid salts, e.g. its salts with hydrochloric, sulphuric, phosphoric, acetic, maleic, tartaric and citric acids. The thioxanthene compound may be prepared by metallizing thioxanthene in the 9-position by reaction with an alkali metal-transferring compound, such as sodamide or an aryl sodium, particularly phenyl or tolyl sodium, or an aryl or alkyl lithium, and reacting the metal thioxanthene simultaneously or subsequently with a halogen acid ester or an aryl sulphonic acid ester of N-methylpiperidino-3-methanol. The reaction is carried out in an inert solvent, e.g. benzene, toluene, dioxan or anisole. Aryl sulphonic acid esters mentioned are benzene- and p-toluene-sulphonic acid esters. In an example, thioxanthene is reacted with phenyl sodium and the product reacted with N-methyl-3-chloromethyl-piperidine. The compound of the invention and its acid salts are useful therapeutically (see Group VI). U.S.A. Specifications 2,368,006, 2,676,971 and German Specification 815,346 are referred to.ALSO:A medicine comprises a therapeutic dose of 9 - (11 - methylpiperidino - 31 - methyl) - thioxanthene and its acid salts. The compounds are stated to have anti-Parkinson effects. Water-soluble acid salts specified are salts with hydrochloric, sulphuric, phosphoric, acetic, maleic, tartaric and citric acids; these salts are also satisfactory for perenteral therapy. U.S.A. Specifications 2,368,006, 2,676,971 and German Specification 815,346 are referred to. |
